Restoration, Not Bypass: Otoferlin Gene Therapy and a New Era in Hearing Loss Treatment
- 1Virginia Tech Carilion School of Medicine Roanoke Virginia USA
- 2Carilion Clinic Department of Surgery—Section of Otolaryngology Roanoke Virginia USA
Abstract
The FDA approval of Otarmeni, an AAV‐based gene therapy for biallelic OTOF‐associated sensorineural hearing loss, represents a conceptual shift in otology: from bypassing defective auditory physiology to restoring it. Unlike cochlear implantation, which circumvents damaged sensory structures, OTOF gene replacement targets a synaptic deficit in a structurally intact cochlea. Early clinical trial data are encouraging, with 75% of evaluable participants—children with molecularly confirmed biallelic OTOF variants enrolled in early‐phase trials—achieving the primary hearing endpoint at 24 weeks. However, critical questions remain regarding long‐term durability, the feasibility of redosing, and the surgical and logistical infrastructure required for intracochlear delivery. This commentary argues that otoferlin gene therapy initiates a new treatment hierarchy rather than rendering cochlear implantation obsolete: restore when biology permits, bypass when it does not. Realizing this potential will require advances in newborn genetic screening, workforce training, and equitable access to gene delivery.
Related
- Integrating Regenerative Medicine and Stem Cell Therapy in Hearing Restoration: A Systematic Review
- Efficacy of sound therapy in chronic tinnitus patients with mild hearing loss: a multicentre, double-blind, placebo-controlled randomized clinical trial
- Burden of treatment associated with hearing aid use among older adults with hearing loss: a qualitative study.
- Commentary: Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity
- Refractory Pseudomonas aeruginosa Bronchopulmonary Infection After Lung Transplantation for Common Variable Immunodeficiency Despite Maximal Treatment Including IgM/IgA-Enriched Immunoglobulins and Bacteriophage Therapy
BibTeX
@article{selvasingh2026restoration,
title = {{Restoration, Not Bypass: Otoferlin Gene Therapy and a New Era in Hearing Loss Treatment}},
author = {Jazlyn A. Selvasingh and Justin R. Shinn},
journal = {Otolaryngology--Head and Neck Surgery},
year = {2026},
month = jul,
doi = {10.1002/ohn.70347},
url = {https://doi.org/10.1002/ohn.70347},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Restoration, Not Bypass: Otoferlin Gene Therapy and a New Era in Hearing Loss Treatment
AU - Jazlyn A. Selvasingh
AU - Justin R. Shinn
PY - 2026
DA - 2026/07/18
JO - Otolaryngology--Head and Neck Surgery
DO - 10.1002/ohn.70347
UR - https://doi.org/10.1002/ohn.70347
AB - The FDA approval of Otarmeni, an AAV‐based gene therapy for biallelic OTOF‐associated sensorineural hearing loss, represents a conceptual shift in otology: from bypassing defective auditory physiology to restoring it. Unlike cochlear implantation, which circumvents damaged sensory structures, OTOF gene replacement targets a synaptic deficit in a structurally intact cochlea. Early clinical trial data are encouraging, with 75% of evaluable participants—children with molecularly confirmed biallelic OTOF variants enrolled in early‐phase trials—achieving the primary hearing endpoint at 24 weeks. However, critical questions remain regarding long‐term durability, the feasibility of redosing, and the surgical and logistical infrastructure required for intracochlear delivery. This commentary argues that otoferlin gene therapy initiates a new treatment hierarchy rather than rendering cochlear implantation obsolete: restore when biology permits, bypass when it does not. Realizing this potential will require advances in newborn genetic screening, workforce training, and equitable access to gene delivery.
SN - 0194-5998
SN - 1097-6817
ER -